Insmed Inc (INSM)
24.80
-0.12
(-0.48%)
USD |
NASDAQ |
Apr 26, 16:00
24.80
0.00 (0.00%)
After-Hours: 20:00
Insmed Research and Development Expense (Quarterly): 137.03M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 137.03M |
| September 30, 2023 | 109.15M |
| June 30, 2023 | 196.97M |
| March 31, 2023 | 127.86M |
| December 31, 2022 | 124.76M |
| September 30, 2022 | 99.87M |
| June 30, 2022 | 88.53M |
| March 31, 2022 | 84.36M |
| December 31, 2021 | 76.35M |
| September 30, 2021 | 70.35M |
| June 30, 2021 | 64.66M |
| March 31, 2021 | 61.39M |
| December 31, 2020 | 67.81M |
| September 30, 2020 | 41.41M |
| June 30, 2020 | 35.75M |
| March 31, 2020 | 36.18M |
| December 31, 2019 | 32.63M |
| September 30, 2019 | 34.34M |
| June 30, 2019 | 33.54M |
| March 31, 2019 | 31.20M |
| December 31, 2018 | 39.92M |
| September 30, 2018 | 39.54M |
| June 30, 2018 | 35.72M |
| March 31, 2018 | 30.10M |
| December 31, 2017 | 33.95M |
| Date | Value |
|---|---|
| September 30, 2017 | 26.68M |
| June 30, 2017 | 26.87M |
| March 31, 2017 | 22.25M |
| December 31, 2016 | 54.87M |
| September 30, 2016 | 23.43M |
| June 30, 2016 | 23.87M |
| March 31, 2016 | 20.55M |
| December 31, 2015 | 19.65M |
| September 30, 2015 | 19.22M |
| June 30, 2015 | 18.25M |
| March 31, 2015 | 17.16M |
| December 31, 2014 | 14.80M |
| September 30, 2014 | 15.20M |
| June 30, 2014 | 14.94M |
| March 31, 2014 | 11.35M |
| December 31, 2013 | 9.625M |
| September 30, 2013 | 12.10M |
| June 30, 2013 | 12.22M |
| March 31, 2013 | 10.33M |
| December 31, 2012 | 11.59M |
| September 30, 2012 | 5.706M |
| June 30, 2012 | 7.745M |
| March 31, 2012 | 4.739M |
| December 31, 2011 | 7.224M |
| September 30, 2011 | 6.933M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
32.63M
Minimum
Dec 2019
196.97M
Maximum
Jun 2023
80.15M
Average
70.35M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| NeuroMetrix Inc | 0.7324M |
| Intra-Cellular Therapies Inc | 50.77M |
| Rhythm Pharmaceuticals Inc | 29.89M |
| Amylyx Pharmaceuticals Inc | 44.91M |
| AN2 Therapeutics Inc | 14.92M |